| dc.creator | Carpio Rodas, Luis Arturo | |
| dc.creator | Romo, M.L | |
| dc.date | 2018-01-11T16:47:23Z | |
| dc.date | 2018-01-11T16:47:23Z | |
| dc.date | 2016-09-01 | |
| dc.date | info:eu-repo/date/embargoEnd/2022-01-01 0:00 | |
| dc.date.accessioned | 2018-03-14T20:32:16Z | |
| dc.date.available | 2018-03-14T20:32:16Z | |
| dc.identifier | 3645134 | |
| dc.identifier | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84985955339&doi=10.1002%2fana.24732&partnerID=40&md5=edf981bc23ff3698f612da2b15e1d055 | |
| dc.identifier | http://dspace.ucuenca.edu.ec/handle/123456789/29095 | |
| dc.identifier | 10.1002/ana.24732 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1135997 | |
| dc.description | Objective: The diagnosis of neurocysticercosis (NCC) remains problematic because of the heterogeneity of its clinical, immunological, and imaging characteristics. Our aim was to develop and assess a new set of diagnostic criteria for NCC, which might allow for the accurate detection of, and differentiation between, parenchymal and extraparenchymal disease. Methods: A group of Latin American NCC experts developed by consensus a new set of diagnostic criteria for NCC. A multicenter, retrospective study was then conducted to validate it. The reference standard for diagnosis of active NCC was the disappearance or reduction of cysts after anthelmintic treatment. In total, three pairs of independent neurologists blinded to the diagnosis evaluated 93 cases (with NCC) and 93 controls (without NCC) using the new diagnostic criteria. Mixed-effects logistic regression models were used to estimate sensitivity and specificity. Results: Inter-rater reliability (kappa) of diagnosis among evaluators was 0.60. For diagnosis of NCC versus no NCC, the new criteria had a sensitivity of 93.2% and specificity of 81.4%. For parenchymal NCC, the new criteria had a sensitivity of 89.8% and specificity of 80.7% and for extraparenchymal NCC, the new criteria had a sensitivity of 65.9% and specificity of 94.9%. Interpretation: These criteria have acceptable reliability and validity and could be a new tool for clinicians and researchers. An advantage of the new criteria is that they consider parasite location (ie, parenchymal or extraparenchymal), which is an important factor determining the clinical, immunological, and radiological presentation of the disease, and importantly, its treatment and prognosis. Ann Neurol 2016;80:434–442. | |
| dc.language | en_US | |
| dc.publisher | JOHN WILEY AND SONS INC. | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights | http://creativecommons.org/licenses/by-nc-sa/3.0/ec/ | |
| dc.source | instname:Universidad de Cuenca | |
| dc.source | reponame:Repositorio Digital de la Universidad de Cuenca | |
| dc.source | Annals of Neurology | |
| dc.title | New diagnostic criteria for neurocysticercosis: Reliability and validity | |
| dc.type | Artículos de revistas | |
